Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2016 · 10-Q
Revenue$5.85M$5.85M+11.2% vs Q1 2015 Net Income$255.63K$255.63KN/M vs Q1 2015 EPS Diluted$0.01$0.01N/M vs Q1 2015 Gross Profit$3,451,419+79.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$2,896,072N/M Free Cash Flowderived-$2,912,701N/M Margins · derivedGross margin59.0%+22.3 pt vs Q1 2015
Operating margin7.8%+25.0 pt vs Q1 2015
Net margin4.4%+23.9 pt vs Q1 2015
ended Apr 2, 2016 · filed May 12, 2016 · 40 d after period end